Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Antibiotic Restrictions Highlighted In Impavido Review

Executive Summary

Advisory committee members, worried about adherence to miltefosine regimen outside the U.S., urge FDA to require directly observed therapy in labeling.

You may also be interested in...



Paladin’s Impavido Poised For Smooth Advisory Committee

FDA reviewers did not identify any major problems with the application for treatment of three types of leishmaniasis, but did say the product may face resistance problems as use expands.

Rare Cancer Development Consortium Moving Toward Target Selection

An upcoming public meeting will include a look at platforms before the first targets are chosen.

Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger

The Barth Syndrome candidate application will be reviewed by the FDA, but Stealth BioTherapeutics' CEO tells the Pink Sheet that the company still does not have clear guidance on how or whether it should gather additional clinical data.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel